uniQure N.V.
AMT-130
Huntington’s disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for AMT-130 in Huntington’s disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA”